National Taiwan University Hospital
Taipei, 10002, Taiwan
Location status: Recruiting
Location contact
Mei-Jyh Chen, MD
CONTACT
NCT Number: NCT04332848
Aim: Therefore, we aimed to
1. compare the efficacy of susceptibility testing guided therapy vs. empirical therapy in the third-line eradication for refractory H. pylori infection 2. assess the long-term impact of eradication therapy on the antibiotic resistance and microbiota of the gut flora and the metabolic factors.
Methods: This will be a multi-center, open labeled trial
Patients: 360 patients with failure to H. pylori eradication for at least two times will be enrolled Determination of antibiotic resistance of H. pylori:
Agar dilution test will be used to determine the minimum inhibitory concentrations of levofloxacin, tetracycline, rifabutin, and clarithromycin to guide the selection of antibiotics.
Treatment regimens and assignment: Eligible patients will be randomized to receive either one of the treatments (A) Susceptibility testing guided therapy or (B) Empirical therapy
Outcome Measurement:
Primary End Point: Eradication rate will be evaluated according to Intent-to-treat (ITT) analyses.
Secondary End Point: 1. Eradication rate according to per protocol analysis (PP analysis); 2. Frequency of adverse effects.
Interested in participating?
Request Info20 year–90 year
All sexes
Interventional
Phase 4
Taipei, 10002, Taiwan
Location status: Recruiting
Mei-Jyh Chen, MD
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Empirical therapy Based on drug history: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin triple/quadruple therapy or concomitant therapy
Susceptibility testing guided therapy Based on susceptibility test: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin triple/quadruple therapy or concomitant therapy
Time frame: 6 weeks
Eradication rate will be determined by urea breath test at least 6 weeks after completion of treatment.
Time frame: 2 weeks
A standard interview and questionaire will be used to assess the adverse effects.
Contact information is provided by the study sponsor or research team.
National Taiwan University Hospital
Other
Comparison of Susceptibility Testing Guided Versus Empirical Therapy for the Third-line Eradication of H. Pylori- a Multicenter Randomized Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07704255
Helicobacter Pylori Infection
Chengdu, Sichuan, China
View Trial DetailsNCT05762991
Helicobacter Pylori Infection, Premalignant Lesion
Taipei, Taiwan
View Trial DetailsNCT07516262
Helicobacter Pylori Infection
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT07439445
Helicobacter Pylori Infection
Beijing, Beijing Municipality, China
View Trial Details